Drug device combination products are defined as the individual products comprising of two regulated components, an active pharmaceutical ingredient and medical device that are chemically or physically combined to produce a single product. The drugs present in the device are either impregnated or surface coated. Combination products have emerged as innovative medical products due to their contribution in advancing medical care and are thus expected to have major impact on the overall medical devices market.
This report covers the market analysis for various drug device combination products from the perspective of product types. The stakeholders for this report include the present manufacturers and providers of drug device combination products as well as the new players who desire to enter this market. This report comprises an executive summary, which provides the market snapshot covering overall information about the various segments and sub-segments of drug device combination products market.
The market overview section of the report explains about the market dynamics and trends such as the drivers, restraints and opportunities that have an influence over current and future status of this market. Degree of competitiveness is explained through Porter’s five forces analysis and the most attractive regional market by type is represented in the market attractiveness analysis section of this report. All these factors will help the market players to decide about the business strategies and plans to be incurred in future for strengthening their position in the global market.
The global drug device combination products market has been differentiated into eight segments based on the product types. The products analyzed in this study are the drug eluting stents, infusion pumps, bone graft implants, photodynamic therapy, wound care combination devices, inhalers, transdermal patches and others (intraoral implants and drug eluting beads). Depending on types, these products are further differentiated into sub segments. Drug eluting stents has been segmented into coronary stents and peripheral vascular stents. Orthopedic combination products market includes two sub segments namely antibiotic bone cement and bone graft implants. Infusion pumps has been segmented into implantable infusion pumps and ambulatory infusion pumps. Inhalers market is further classified into three segments namely nebulizers, metered dose inhalers and dry powder inhalers. Each of the above product segments and sub-segments are analyzed on the basis of market size in terms of USD million for the period 2011 - 2019 along with compounded annual growth rate (CAGR %) for the period, considering 2012 as the base year.
Geographically, the drug device combination products market has been classified into four major segments namely, North America, Europe, Asia Pacific and Rest of the World. Market revenue for 2011 to 2012 and forecast for 2013 to 2019 for drug device combination products is analyzed in this report. This section also provides the CAGR % of each geographical region for the forecast period of 2013 to 2019. A competitive landscape, mapping all the market players and their respective market shares for 2012 are provided in this report for drug eluting stents and infusion pumps. A list of recommendations is also provided in this report to help market players in increasing their market share and new entrants in establishing their strong position in the market.
The report concludes with the company profile section which covers the key information such as company overview, financial overview, product portfolio, business strategies and recent developments about the major market players in the drug device combination products. Some of the major companies which are profiled in this report include Abbott Laboratories, Allergan, Inc., Alcon, Inc., Arrow International, Inc., Boston Scientific Corporation, CareFusion Corporation, Covidien PLC, C.R. Bard, Inc., Ethicon, Inc., Medline Industries, Inc., Medtronic, Inc., Mylan, Inc., Pinnacle Biologics, Inc., Stryker Corporation, Terumo Corporation, W.L. Gore & Associates, Inc.